Inactivation of gentamicin (G) is known to occur secondarily to the formation of complexes with certain betalactam antibiotics. However, aminoglycosides in the presence of aminoglycoside-beta-lactam complexes may not be recognized uniformly by all assay methods. We tested this hypothesis by using mixtures of G plus carbenicillin (C), with and without the addition of penicillinase, in pooled sera under several in vitro conditions: at 25 and 35°C and at low and high C concentrations. Samples were assayed for G with the EMIT and TDx systems, and a microbiological assay was performed with a strain of Kkebsiella pneumoniae resistant to C. In the presence of C (500 ,Iglml) at 35°C, the initial G concentration of 5 uLg/ml decreased markedly over 48 h as assessed by all three assay methods. However, significantly greater degradation was noted when samples were measured by microbiological assay and TDx than by EMIT. Differences between assays were less marked when mixtures were studied at a lower temperature and with a lower G to C ratio (5 ,ug of G plus 100 ,ug of C per ml). The addition of penicillinase to the antibiotic mixtures prevented the degradation of G over time when measured by all three assay systems. We concluded (i) that EMIT measures higher serum concentrations of G than do TDx or microbiological assays when complexes of G and C are present and (ii) that the addition of penicillinase to serum samples containing C and G would be effective in preventing G degradation during prolonged (>24-h) periods between the time of sampling and assay.
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Apparent inactivation of gentamicin via formation of complexes with carbenicillin or other beta-lactam antibiotics is known to occur both in vitro and in vivo (8, 12, 13) . Inactivation in vivo has been described primarily in patients with severe renal impairment (2, 13, 14, 17) . The assay methods used to quantify the extent of gentamicin inactivation have included radioimmunoassay (3, 6, 12, 14) , radioenzymatic assay (5, 10, 11, 16) , and high-pressure liquid chromatography (11) . All of these assay methods have been able to demonstrate inactivation that is comparable in extent to that seen with microbiological assays (BAs), which measure only biologically active gentamicin in vitro (10, 12, 14, 16) . However, comparisons of the EMIT method (enzymelinked immunoassay) (Syva Co., Palo Alto, Calif.), or the TDx method (Abbott Laboratories, North Chicago, Ill.), a fluoropolarimetric assay, each of which is a common clinical assay, with microbiological methods for characterizing this inactivation have yet to be described.
We questioned whether the EMIT or TDx assay system for gentamicin would be able to distinguish active gentamicin as measured by BA in the presence of gentamicin-carbenicillin complexes. Our suspicions were based on serum gentamicin concentration values measured by EMIT which Were consistently higher than values measured by BA in patients who had received concomitant carbenicillin therapy. The following case is an example of such an occurrence: a 64-year-old female with a long history of diabetes mellitus was admitted to our institution for treatment of a case of right lower extremity osteomyelitis. The patient had a substantial degree of renal dysfunction (serum creatinine, 5.5 mg/dl; blood urea nitrogen, 96 mg/dl). The osteomyelitis progressed despite antibiotic therapy, and a below-the-knee amputation was performed. Subsequently, the patient became febrile and developed an infection at the site of amputation, which, when cultured, revealed the presence of Pseudomonas aeruginosa. Therapy with carbenicillin (2 g intravenously [i.v.] every 6 h) and gentamicin (60 mg i.v. every 12 h) was begun. After 4 days of combined therapy, a sample of serum was obtained for assay immediately after a dose of carbenicillin was injected and 6 h after the last dose of gentamicin was injected. The sample was assayed for gentamicin ca. 12 h later. The measured gentamicin concentration was 3.9 ,ug/ml by the EMIT method but less than 1.0 pug/ml by BA Effect of temperature. A comparison of mixtures of gentamicin (5 ,ug/ml) plus carbenicillin (500 ,ug/ml) incubated at 35 and 25°C showed an increased rate of gentamicin degradation at the higher temperature (Table 2) . For EMIT and TDx assays, the differences due to temperature did not achieve statistical significance until after 24 h, whereas with the BA a significant difference was noted as early as 6 h after mixing.
After 48 h at 35°C in the presence of carbenicillin (500 ,ug/ ml), gentamicin declined to 14.9 ± 3.1% of initial concentrations when measured by BA and 17.4 ± 0.1% by TDx. However, a significantly greater fraction of gentamicin (52.5 ± 7.0%) was measured by the EMIT method under these conditions. Significant differences were also noted between the EMIT method and the other two assays in the fraction of DISCUSSION The results of this study suggest that the EMIT system measures higher gentamicin values than the TDx and BA when gentamicin-carbenicillin complexes are present in sufficient concentrations. Since the assays all correlated well in the presence of carbenicillin but before inactivation, the differences in the measured gentamicin concentrations in the presence of carbenicillin as measured by EMIT versus TDx and BA cannot be explained by differences in precision or sensitivity among the three different assay methods.
Mixtures which showed the greatest extent of inactivation (i.e., 5 ,ug of gentamicin plus 500,ug of carbenicillin per ml at 35°C for 48 h) demonstrated the largest discrepancies between EMIT and the other two assays. Tonversely, in mixtures with little inactivation or in early (i.e., 6-h) specimens, little or no discrepancy was observed. For example, a mixture of 5 jig of gentamicin and 500 ,ug of carbenicillin per ml at room temperature for 48 h yielded 61.8 ± 3.1% of initial concentrations by EMIT compared with 29.2 ± 3.2% by BA (P < 0.001) and 32.9 ± 0.7% by TDx (versus EMIT, P < 0.001). Under conditions in which minimal gentamicin inactivation occurred (i.e., 5 ,Ig of gentamicin plus 100 ,ug of carbenicillin per ml at 25°C for 6 h), broad agreement between each of the three assays was observed.
The mechanism most consistent with our findings is that of a decline in gentamicin concentrations when gentamicin is combined with carbenicillin, with a concurrent increase in gentamicin-carbenicillin complexes. The ability of the EMIT system to differentiate these complexes from parent gentamicin appears to be less specific. Since the TDx assay was in good agreement with the BA, this method appears to be more specific in measuring biologically active gentamicin than the EMIT assay. In only two experimental conditions were the TDx values significantly greater than the values obtained from BA (Table 2 ). These observations are compatible with the longer incubation time required by BA (4 h). An alternative explanation is provided by the regression analysis of each assay method compared with spiked concentra- The results of this study showing a dependency of the rate and extent of gentamicin inactivation upon carbenicillin concentration, length of incubation, and temperature are similar to those reported by others (6, 10) . Pickering and Gearhart (10) showed that the extent of gentamicin inactivation during incubation in human sera with carbenicillin (600 jig/ml) at 24 h was 41 + 19% of the initial concentration.
Further inactivation occurred at 72 h resulting in only 17 + 4.3% of initial gentamicin remaining. In that study, gentamicin was measured by using a radioenzymatic method. Although the experimental conditions were slightly different than those in the present study, the fraction of gentamicin remaining at 24 h was similar to our values when measured by BA (35.6 ± 7.2%) and TDx (38.1 ± 0.3%) but not by EMIT (62.3 ± 7.0%).
Preliminary data of interest demonstrating that the EMIT method incompletely detects the aminoglycoside-beta-lactam interaction under in vitro conditions when compared with the BA have been recently reported (M. Pfaller, G. Granich, and P. Murray, Abstr. Annu. Meet. Am. Soc. Microbiol. 1983 , C314, p. 364).
Since inactivation of gentamicin by carbenicillin via amide formation results in minimal structural changes in the gentamicin molecule (4), it is possible that the antibody used in the EMIT gentamicin assay displays some affinity for the inactivated species, resulting in elevated gentamicin values. The product information booklet included with the gentamicin assay kit does not address possible cross-reactivity of gentamicin-beta-lactam complexes with the assay antibody (Product Information, Gentamicin EMIT Assay, Syva Company, Palo Alto, Calif.). Interference of structurally related compounds has been shown to occur for other EMIT assays; Aldwin and Kabakoff (1) demonstrated affinity of the EMIT phenytoin assay for the p-hydroxylated metabolite of phenytoin. Pape (9) described cross-reactivity of the EMIT lidocaine assay with the anesthetic mepivacaine.
From a clinical standpoint, the majority of serum samples from patients receiving both gentamicin and carbenicillin therapy contain 100 pg of carbenicillin or less per ml and would be assayed for gentamicin within 6 to 8 h after sampling. For these samples, either the TDx or EMIT gentamicin assay would be adequate, since minimal in vitro gentamicin inactivation was shown to occur during this time interval and at low concentrations of carbenicillin.
In contrast, in samples from patients with higher serum carbenicillin concentrations (i.e., those with poor renal function, receiving full doses of carbenicillin), the rate of in vitro inactivation of gentamicin is greater; however, differences in measured gentamicin concentration between EMIT, TDx, and BA are still minimal after 6 h at room temperature. The extent of inactivation (11 to 18%) by these three assays may be important when precise dose adjustments are warranted. However, if these samples were to remain at room temperature for longer periods of time (24 to 48 h), a substantial amount of inactivation would occur, and important differences would exist between EMIT and the other two methods. Therefore it would appear prudent to add penicillinase to these samples. Based on previous work, storage of samples at -70°C also appears to prevent gentamicin inactivation, and this would be an alternative procedure.
The clinical assay of choice of samples left for prolonged (24 h or more) periods of time or of those from patients with severely impaired renal function, in which in vivo inactivation may occur, is uncertain. The EMIT assay will minimize effects of in vitro inactivation because of its nonspecificity; however, it may overestimate biologically active gentamicin concentrations in patients with in vivo production of gentamicin-carbenicillin complexes. The issue of whether these complexes should be measured (i.e., whether they are toxic or are hydrolyzed in vivo to yield active gentamicin) has yet to be resolved.
The results of this study suggest (i) that it is possible to demonstrate that the EMIT gentamicin assay measures higher gentamicin concentration values than do TDx or BA when gentamicin-carbenicillin complexes are present, (ii) that either EMIT or TDx may be used to measure gentamicin concentrations in the majority of patients receiving carbenicillin if the assay is performed promptly after sampling, (iii) that serum samples containing gentamicin and carbenicillin which are not to be assayed promptly (i.e., within 24 h) will show less inactivation by EMIT than by the other two assays but should have penicillinase added to them to prevent excessive in vitro inactivation, and (iv) that the therapeutic and toxic potential of gentamicin-carbenicillin complexes formed in vivo in patients with severe renal dysfunction should be investigated before their clinical significance can be assessed.
